SSR 103800

Drug Profile

SSR 103800

Alternative Names: SSR 103800A; SSR103800

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antipsychotics
  • Mechanism of Action Glycine reuptake inhibitors; Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in France (PO)
  • 03 Sep 2008 Pharmacodynamics data from preclinical trials in Schizophrenia presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
  • 17 Oct 2007 Pharmacodynamics data from a preclinical trial in an animal model of Schizophrenia presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top